8-K/A
filed January 13, 2025, 6:59 PM ET
ticker ABVC
CIK 0001173313
regulatory
confidence high
sentiment neutral
materiality 0.50
ABVC BioPharma granted additional 180-day Nasdaq bid price compliance extension to July 7, 2025
ABVC BIOPHARMA, INC.
- Nasdaq extended deadline from January 6, 2025 to July 7, 2025 for minimum $1.00 bid price requirement.
- Company must close at $1.00 or higher for at least 10 consecutive trading days to regain compliance.
- ABVC may consider a reverse stock split to meet the bid price requirement.
- No immediate impact on Nasdaq listing; stock continues trading under symbol ABVC.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-25-002769
- form_type
- 8-K/A
- ticker
- ABVC
- cik
- 0001173313
- company_name
- ABVC BIOPHARMA, INC.
- filed_at
- 2025-01-13T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:03.082307+00:00
- generated_at
- 2026-05-28T02:48:22.596128+00:00
- sec_items
- ["3.01", "7.01", "9.01"]
- event_type
- regulatory
- sentiment
- neutral
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-25-002769
- json_url
- https://secwatch.observer/filing/0001213900-25-002769.json
- markdown_url
- https://secwatch.observer/filing/0001213900-25-002769.md
- text_url
- https://secwatch.observer/filing/0001213900-25-002769.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/ea0227316-8ka1_abvcbio.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
IVF
INVO Fertility receives Nasdaq deficiency notice for late 10-K filing
INVO Fertility, Inc.
April 29, 2026, 7:59 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
April 23, 2026, INVO Fertility, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications
staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company failed to fi
Filing page
SEC filing
FTHM
Fathom Holdings receives Nasdaq notice for late Q1 2026 10-Q filing; 60 days to submit plan
Fathom Holdings Inc.
May 29, 2026, 4:15 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
May 22, 2026, Fathom Holdings Inc. (the “Company”) received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the “Filing Requirement”). In accordance with Nasdaq’s listing rules, the Company has 60 calendar days from the date of the notification letter
Filing page
SEC filing
LASE
Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q
Laser Photonics Corp
May 22, 2026, 5:27 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
received a notice from Nasdaq Listing Qualifications
department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q
for the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated
that the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception
to allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or
November 16, 2026. A
copy of t
Filing page
SEC filing
RICK
RCI receives Nasdaq noncompliance notice for late Q2 10-Q; deadline July 20
RCI HOSPITALITY HOLDINGS, INC.
May 22, 2026, 4:23 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
May 20, 2026, RCI Hospitality Holdings, Inc. (“we,” “us” and the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that we are
Filing page
SEC filing
AVXL
Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026
ANAVEX LIFE SCIENCES CORP.
May 22, 2026, 8:15 AM ET
regulatory
Items 3.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
May 20, 2026, Anavex Life Sciences Corp. (the “Company”)
received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market
LLC (“Nasdaq”) indicating that, as
Filing page
SEC filing
GTBP
GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price
GT Biopharma, Inc.
May 22, 2026, 8:00 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications
Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that
Filing page
SEC filing
ONFO
Onfolio Holdings regains Nasdaq minimum bid price compliance
Onfolio Holdings, Inc
May 1, 2026, 7:59 PM ET
regulatory
Items 3.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
January 6, 2026, Onfolio Holdings Inc. (the “ Company ”) received notice from The NASDAQ Stock Market that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days a
Filing page
SEC filing
AREC
American Resources receives Nasdaq non-compliance notice for late 10-K filing; has 60 days to submit plan
American Resources Corp
April 30, 2026, 7:59 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company")
received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement
of $1.00 per share, as
Comparable filing
April 24, 2026, American Resources Corporation (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to t
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.